Elypta was selected as one of twelve start-ups across Europe to present at BIO Europe Spring Start-up Spotlight event. Karl Bergman will be in Vienna for the event on March 26th.
The Horizon 2020 award announcement has led to increased interest in Elypta’s activities. 360Dx interviewed Karl Bergman (CEO) and Saeed Dabestani, Urologic surgeoun at Skåne University Hospital, senior associate at the European Association of Urology, Guidelines panel for RCC and medical advisor to Elypta on the application of the technology in RCC. Full article here.
Elypta today announced it is one of the winners in the European Union’s Horizon 2020 Research and Innovation Programme SME instrument phase 2 and has been awarded Euros 2.35 m. The grant will fund the first ever multicenter trial for diagnoses of renal cell carcinoma (RCC), aimed at validating the company's innovative metabolism-based liquid biopsy platform for early detection of recurrent RCC and thus enabling the test to be launched in Europe and the US.
Select press coverage:
Elypta’s CSO Francesco Gatto was today included in the European edition of MIT Technology Review’s annual 35 Innovators Under 35 for the ground breaking research he leads at Elypta.
We are delighted to announce that Elypta yet again qualified as a global top 500 DeepTech start-up in the annual competition held by Hello Tomorrow. We will attend the finals at the Global Summit in 2019.
As of January, Anders Ekblom has joined the team. Anders brings a wealth of experience from the life science and healthcare industries and is a great addition to Elypta's board of directors.
We are delighted to announce that Elypta has been chosen by Hello Tomorrow Nonprofit as one of the world’s TOP 500 deep-tech startups! Elypta is one of 50 companies progressing in the Healthcare track. Come meet us at the HTSummit in Paris this October.